Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu maintained a Buy rating on Protara Therapeutics, lowering the price target from $26 to $20. The decision reflects confidence in the company's strategic trial shift for TARA-002, which aims to accelerate data generation and broaden commercial opportunities. Zhu also cited a solid balance sheet with cash runway into 2028 and clear clinical milestones as key factors supporting the favorable risk-reward profile despite the reduced valuation.
Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Protara Therapeutics, reducing the price target to $20.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Charles Zhu has given his Buy rating due to a combination of factors, including Protara’s strategic shift in trial design that is intended to accelerate and broaden clinical data generation for TARA-002 in non-muscle invasive bladder cancer. By converting ADVANCED-3 into an open-label exploratory study that spans both BCG-naive and BCG-exposed high‑grade populations, management is positioning the asset for a more expansive commercial opportunity at the time of a potential BCG‑unresponsive launch.
Zhu also emphasizes the company’s refined clinical milestones and solid balance sheet, noting that Protara has laid out clear timelines for key readouts across ADVANCED-2, STARBORN-1, and THRIVE-3 while maintaining cash runway into 2028. Coupled with management’s confidence in achieving a clinically meaningful complete response rate in BCG-unresponsive disease and the prospective compendia listing that could unlock access to roughly 20,000 U.S. patients, he sees a favorable risk‑reward profile that justifies a Buy rating despite revising the price target to $20 from $26.